Company Overview - NEXGEL creates custom hydrogel solutions and develops patented medical devices, custom/white label products, and OTC healthcare consumer products[7] - The company has agreements with multi-billion dollar corporations[9] - NEXGEL has one of two state-of-the-art manufacturing facilities in North America that can produce hydrogel transdermal products[14] - The facility has a total capacity of over 1.4 billion square inches of product per year[15] Strategic Partnerships - Cintas Corporation will distribute NEXGEL's SilverSeal wound care solution to its customers[41] - STADA Arzneimittel AG is partnering with NEXGEL to expand its OTC product portfolio, with their first joint product, Histasolv, generating over $20 million in annualized European revenue[42] - CG Converting and Packaging is the exclusive supplier of gel pads for AbbVie's Rapid Acoustic Pulse device, with AbbVie acquiring Soliton for $550 million in December 2021[43] Financial Performance - Q2 2025 revenue was $2.88 million, a 100% increase compared to $1.44 million for Q2 2024[50] - Q2 2025 gross profit was $1.26 million with a profit margin of 43.6%, compared to 20.3% in Q2 2024[50] - The company reiterates revenue guidance of $13 million for 2025 and expects to achieve positive EBITDA during the year[50] Acquisitions - Silly George Beauty Brand was acquired in May 2024 and has an annual run-rate of over $5 million[36] - Kenkoderm Skincare Line was acquired in December 2023 and is immediately accretive[40]

Company Overview - ClearPoint Neuro enables cell, gene, and device therapies by offering precise navigation to the brain and spine[6] - The company's platform includes clinical products for neurosurgeons and drug development services for BioPharma partners[6] - ClearPoint Neuro has built a complete drug delivery ecosystem over 15+ years[8] - The company has 100+ active global centers and 60+ partners across 20+ indications[8] Market Opportunity - The company estimates its current portfolio provides access to a ≈$500 million market opportunity[8] - ClearPoint Neuro sees a $10 billion potential diversified market[9] - Over 30 million people in the U S are estimated to suffer from severe and debilitating neurological disorders[10] - Neurological diseases cost Americans nearly $800 billion annually[10] Financial Performance - The company's 2024 revenue was $31.4 million[52] - As of June 30, 2025, the company had $41.5 million in cash and cash equivalents[52] - The company's gross margin is 60%[52] - The company's 2024 operational cash burn was ($9.0 million)[52]

Financial Performance - Telecom Argentina's 1H25 adjusted EBITDA reached $399 million, a 54% increase compared to 1H24[12] - The company reported a 30% EBITDA margin in 1H25, compared to 29.7% in 1H24[12, 28] - Telecom Argentina's 1H25 CAPEX totaled $359.336 million[81] - Telecom Argentina raised a total of approximately $2.6 billion in USD equivalent through various transactions[105] Telefónica Móviles Argentina (TMA) Acquisition - The acquisition of TMA contributed to a proforma revenue of $4.009 billion and EBITDA of $1.129 billion for FY24[24] - TMA's 1H25 figures include just four months of contribution to Telecom Argentina's consolidated results[24] - Actions are being taken to improve TMA's EBITDA margin, targeting an 11% margin as reported in 1H25[33] Operational Highlights - Personal Pay, Telecom Argentina's digital wallet, has onboarded over 4.2 million clients, representing a 44% year-over-year increase[12, 64] - Mobile ARPU evolution in US$ increased by 15% for TMA and 19% for TEO[48] - Broadband ARPU evolution in US$ increased by 12% for TMA and 22% for TEO[48] Debt Management - Successful issuance of Class 24 Notes for $800 million in May and a tap for $200 million in July, reducing the bond's average financing cost from 9.50% to 9.36%[12] - The company has a balanced debt maturity profile, with approximately 72% of debt in US dollars, RMB, and Guaraní[111] Regulatory and Environmental - Telecom Argentina submitted its comments to the CNDC regarding the June 19 technical opinion[37] - Telecom Argentina's near-term science-based targets have been approved, reinforcing the company's environmental commitments[115]

Financial Performance & Growth - The company's last twelve months (LTM) global proforma revenue is $564 million[6] - The company is experiencing above-market revenue growth, with seven quarters of mid-single-digit or higher growth[7] - The company's organic growth is projected at 7.0% in 2025[11] - The company's Adjusted EBITDA margin is steadily increasing, projected to reach 20.2% in 2025[14] - Cash from operations is increasing, with 2025 projected to be nearly double that of 2024[18] - Net leverage ratio is decreasing, projected to be less than 2.5x by the end of 2025[28] Market & Strategy - The company operates in a $6.4 billion addressable market[6] - The company has a diversified portfolio across Pain Treatments, Surgical Solutions, and Restorative Therapies[5, 20] - The company is focused on margin expansion by leveraging mid-70s gross margin and cost efficiencies[7, 25] - The company aims to nearly double 2024 free cash flow in 2025, with a cash flow yield of approximately 60%[28]

Financial Performance & Guidance - Methode Electronics reported FY25 sales of $1.05 billion[13, 30] and adjusted EBITDA of $43 million[30] - The company's Q4 FY25 free cash flow reached $26 million, the highest since FY23[8, 30] - FY26 guidance projects sales between $900 million and $1 billion[36], with a midpoint of $950 million[34], and EBITDA between $70 million and $80 million[30, 36], with a midpoint of $75 million[34], representing a 100%+ increase in EBITDA despite ~$100 million lower sales[10, 37] - The company anticipates $58 - $63 million in Depreciation and Amortization, $24 - $29 million in CapEx, $21 - $23 million in Interest Expense and $17 - $21 million in Tax Expense for FY26[36] Business Segments & Growth - In FY25, Automotive segment accounted for 45% of sales, Industrial 40%, and Interface 15%[13] - User Interface solutions represented 45% of sales, Lighting 27%, Power 24%, and Sensors 2%[13, 19] - The company achieved record power product sales in data centers exceeding $80 million in FY25, with similar or greater sales expected in FY26[8, 37] Market & Strategic Outlook - A reset of EV sales is expected in FY26 due to a slowdown in the North American market, particularly driven by Stellantis, with a return to growth anticipated in FY27[9] - Awards of $1.0+ billion in annual sales were secured from FY22 to FY25[30] - The company is focused on transformation, prioritizing improved execution before growth, emphasizing "Earning the Right"[8, 26, 37]

Clinical Programs & Data - Tenaya Therapeutics has 3 clinical-stage programs focused on heart disease [9] - TN-201 for MYBPC3-associated HCM plans data release including longer-term follow-up for Cohort 1 (3E13 vg/kg) and initial safety and biopsy results for Cohort 2 (6E13 vg/kg) in Q4'25 [15] - TN-401 for PKP2-associated ARVC plans data release will include initial Cohort 1 (3E13 vg/kg) data focused on safety and biopsy results in Q4'25 [16] - Interim Cohort 1 TN-201 data showed improvements in ≥ 1 measures of hypertrophy in two of three patients [17] Disease & Patient Populations - MYBPC3-associated HCM is estimated to affect 120,000 people in the U S alone [22] - Approximately 57% of identified genetic variants underlying familial HCM are MYBPC3 mutations [22] - Over 30% of genetic variants underlying childhood-onset HCM are MYBPC3 mutations [22] - PKP2-associated ARVC is estimated to affect >70,000 people in the U S [75] - In ARVC patients, >15% of heart-related deaths in patients < 35 are due to ARVC [75] - In ARVC patients, 23% of ARVC patients present with sudden cardiac death [75] - In ARVC patients, 40% of ARVC patients carry pathogenic PKP2 mutations [75] Capabilities & Milestones - Tenaya has cGMP AAV manufacturing scale achieved; 1000L clinical supply for TN-201 and TN-401 ready [115]

Company Overview - Eagle Point Income Company (EIC) aims to generate high current income and capital appreciation by investing primarily in junior debt tranches of CLOs, with a focus on BB-rated CLO debt[13] - As of June 30, 2025, the total market capitalization of EIC is $501 million[13] - EIC pays a monthly distribution of $0.13 per share, resulting in a distribution rate of 12.0%[13] - The Adviser and Senior Investment Team have approximately $0.8 million invested in EIC, EICA, EICB and EICC[23] CLO Market and Strategy - BB-rated CLO debt has historically exhibited a low default rate of approximately 4 bps per annum from 1994 through Q1 2025[14, 29] - The cumulative default rate on BB-rated CLO debt was 1.1% from 1994 through Q1 2025[29] - The company focuses primarily in junior debt tranches of CLOs, with a focus on BB-rated CLO debt[31] - The CLO market is the largest source of capital for the US senior secured loan market[40] - From 1992 through 2024, the S&P UBS Leveraged Loan Index generated positive total returns in 30 of the 33 full calendar years[42] Portfolio Information (Q2 2025) - The weighted average effective yield on the CLO portfolio was 10.63%[52] - The company's CLO debt investments totaled $379.8 million, and CLO equity investments totaled $127.1 million[52] - The company has exposure to 1,464 unique underlying borrowers[57]

Financial Performance & Growth - Clover Health anticipates insurance revenue of $1.8 billion to $1.875 billion for full year 2025[50] - The company projects Adjusted EBITDA between $50 million and $70 million for full year 2025[9, 50] - Clover Health expects a 32% year-over-year increase in Medicare Advantage (MA) membership in 2025[9, 44] - Clover Health's Insurance Benefits Expense Ratio (BER) for the first half of 2025 was 87.3%[24] Clover Assistant & Clinical Outcomes - Clover Assistant (CA) is associated with earlier diagnosis of Chronic Kidney Disease (CKD) by approximately 18 months on average[18] - Clover Assistant is associated with 15% lower all-cause hospitalizations and 18% lower 30-day readmissions for members with Chronic Obstructive Pulmonary Disease (COPD)[18, 20] - Clover Health achieved a 4.94 out of 5 Stars on HEDIS measures for Star Rating year 2025, the top-performing score on core HEDIS measures for Medicare Advantage plans with over 2,000 members nationwide[18] Strategic Initiatives - Clover Health is focused on a ~$500 billion market with over 35 million seniors enrolled in Medicare Advantage[8] - Clover Health's Counterpart Health subsidiary aims to expand the company's care model to more plans and providers[8] - Approximately 97% of Clover Health's membership is enrolled in PPO plans[8, 49]

Company Overview - Beasley Media Group's future growth will be driven by operational efficiency in its core business and expansion of its digital capabilities[12] - The company operates in 12 US markets[13] - The company's multimedia platform enables local businesses to maximize audience reach[28] Financial Performance - Q2 2025 - Total net revenue was $53 million[47] - Digital revenue accounted for 25% of total net revenue[23] - Same-station digital revenue grew by 81% year-over-year[23] - Station Operating Income (SOI) was $82 million[47] - Adjusted EBITDA was $47 million[47] Revenue Mix - Audio revenue for Q2 2025 was $398 million[23] - Digital revenue for Q2 2025 was $132 million[22] - Local advertisers accounted for 76% of Q2 2025 revenue[25]

Financial Performance & Position - HighPeak Energy reported Q2 2025 production of 48600 barrels of oil equivalent per day (MBoe/d)[14] - The company's Q2 2025 unhedged EBITDAX per BOE was $3358[14] - Q2 2025 EBITDAX totaled $156 million[14] - As of June 30, 2025, the company's pro forma total debt was $12 billion, with a net debt of $1032 billion[16] - The company's total liquidity stood at $268 million, including $168 million in cash and cash equivalents[16] Debt & Hedging - HighPeak Energy extended its Term Loan and Revolving Credit Facility maturities to September 2028 and upsized the Term Loan to $12 billion[21] - Approximately 53% of the company's oil volumes and 89% of gas volumes are hedged for the second half of 2025[25] Operational Efficiency - The company achieved savings of approximately $400000 per well by using Lorin Pad Simulfrac[29] - Simulfrac savings led to a 10% reduction in completion costs[30] - Solar savings from June to December 2024 amounted to $809487, with a CO2 reduction of 4616 metric tons[34] Asset Base - HighPeak Energy has over 143000 net acres[14,35] - The company has over 1000 sub $50/Bbl break-even locations in primary zones[14,35]